{"url_path":"/sec/atyr/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1339970/0001339970-26-000036-index.html","accession_number":"0001339970-26-000036","cik":"0001339970","ticker":"ATYR","issuer_name":"aTYR PHARMA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1339970/0001339970-26-000036-index.html","primary_entity_key":"0001339970","primary_entity_name":"aTYR PHARMA INC"},"word_count":163,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\naTyr Pharma, Inc. (the Company) intends to use an investor presentation to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website. A copy of the presentation materials is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company does not undertake to update the presentation materials.\n\nThe information under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing."}